Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
British Journal of Clinical Pharmacology|July 2, 2026
UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, et al.
British Journal of Cancer|November 23, 2020
The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancerPeter G Alexander, Antonia K Roseweir, Kathryn A F Pennel, et al.
Journal of the American Society of Nephrology : JASN|June 19, 2026
Comparing Catheters to Fistulas in Older Patients Starting Hemodialysis (ACCESS HD)Robert R Quinn, Matthew J Oliver, Ron Wald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2021
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III TrialMary F Mulcahy, Armeen Mahvash, Marc Pracht, et al.
Annals of Neurology|March 28, 2020
Antiepileptic Drug Teratogenicity and De Novo Genetic Variation LoadPiero Perucca, Alison Anderson, Dana Jazayeri, et al.
The Lancet. Gastroenterology & Hepatology|September 4, 2019
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam-Hogan, Fay Cafferty, Richard Hubner, et al.
Neurology|January 14, 2026
Transcription Factor Binding and Individual Genetic Risk of Valproate TeratogenicityAlison Anderson, Piero Perucca, Elena Vianca, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trialPaula Ghaneh, Daniel Palmer, Silvia Cicconi, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 29, 2024
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumorsKathryn A F Pennel, Phimmada Hatthakarnkul, Colin S Wood, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Pageof 7